Roth Capital Terminates Biotie Therapies Oyj (ADR)(NASDAQ:BITI)

Brokerage firm Roth Capital Terminates its rating on Biotie Therapies Oyj (ADR)(NASDAQ:BITI). In a research note issued to the investors, the brokerage major Removes the price-target to $ per share. Previously, the analysts had a Neutral rating on the shares. The rating by Roth Capital was issued on Apr 12, 2016.

In a different note, On Mar 21, 2016, RBC Capital said it Downgrades its rating on Biotie Therapies Oyj (ADR). In the research note, the firm Lowers the price-target to $35.00 per share. The shares have been rated ‘Sector Perform’ by the firm.

Biotie Therapies Oyj (ADR) (BITI) shares turned negative on Fridays trading session with the shares closing down -0.07 points or -0.26% at a volume of 9,624. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $26.75. The peak price level was also seen at $26.75 while the days lowest was $26.4. Finally the shares closed at $26.43. The 52-week high of the shares is $26.989 while the 52-week low is $12.43. According to the latest information available, the market cap of the company is $323 M.

Biotie Therapies Oyj (ADR)(BITI) last announced its earnings results on Mar 18, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $846.37K. Analysts had an estimated revenue of $840.00K. Earnings per share were $-0.01. Analysts had estimated an EPS of $-0.41.

Biotie Therapies Oyj is a Finland-based drug development company focused on developing products for neurodegenerative and psychiatric disorders. The Company’s lead market product is Selincro (nalmefene) a therapeutic for alcohol dependence that is rolled out across Europe by its partner Lundbeck. Its product pipeline includes tozadenant a therapeutic for Parkinson’s disease that is in Phase Three development; and two additional compounds in Phase Two development that treat cognitive disorders namely: SYN120 an orally administered compound therapeutic for Parkinson’s disease dementia and BTT1023 a human monoclonal antibody targeting compound therapeutic for primary sclerosing cholangitis. The Company operates as a subsidiary of Biotie Therapies Corp.

Leave a Reply

Biotie Therapies Oyj (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Biotie Therapies Oyj (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.